Needham & Company LLC Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $202.00

Sarepta Therapeutics (NASDAQ:SRPT - Free Report) had its price target decreased by Needham & Company LLC from $205.00 to $202.00 in a research report report published on Wednesday, MarketBeat Ratings reports. Needham & Company LLC currently has a buy rating on the biotechnology company's stock.

A number of other equities research analysts have also commented on SRPT. Piper Sandler lowered their price target on Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. William Blair raised shares of Sarepta Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Guggenheim increased their price objective on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, Raymond James restated an "outperform" rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $175.77.

Sarepta Therapeutics Stock Up 4.1 %

NASDAQ SRPT traded up $5.38 during mid-day trading on Wednesday, hitting $135.88. The company's stock had a trading volume of 1,598,061 shares, compared to its average volume of 1,242,481. The firm has a market capitalization of $12.98 billion, a price-to-earnings ratio of 104.40 and a beta of 0.81. The company's 50 day simple moving average is $121.90 and its 200 day simple moving average is $131.39. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a twelve month low of $78.67 and a twelve month high of $173.25.

Insider Activity

In other news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares in the company, valued at approximately $4,662,822.56. This trade represents a 14.99 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds have recently bought and sold shares of the stock. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at about $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the first quarter worth approximately $32,000. Sunbelt Securities Inc. lifted its holdings in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Nkcfo LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at $43,000. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.